CytomX Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $1,418 | $10,258 | $663 | $5,963 |
Gross Profit | 1,418 | 10,007 | 663 | 5,963 |
EBITDA | -20,308 | -17,938 | -25,946 | -14,037 |
EBIT | -20,606 | -18,189 | -26,456 | -14,171 |
Net Income | -20,666 | -18,248 | -26,510 | -14,229 |
Net Change In Cash | 1,418 | 10,258 | 663 | 5,963 |
Free Cash Flow | -18,068 | -25,549 | -23,444 | -15,421 |
Cash | 17,224 | 28,828 | 12,667 | 34,185 |
Basic Shares | 218,939 | 177,273 | 170,186 | 165,004 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $76,201 | $138,103 | $101,214 | $53,163 |
Gross Profit | 76,201 | 138,103 | 101,214 | 53,163 |
EBITDA | -15,754 | 33,861 | 5,498 | -98,892 |
EBIT | -17,130 | 32,093 | 3,323 | -101,335 |
Net Income | -17,368 | 31,869 | -569 | -97,299 |
Net Change In Cash | 76,201 | 138,103 | 101,214 | 53,163 |
Cost of Revenue | 13,671 | |||
Free Cash Flow | -75,807 | -86,541 | -56,875 | -112,528 |
Cash | 12,667 | 38,052 | 17,171 | 193,650 |
Basic Shares | 137,935 | 84,745 | 73,808 | 65,739 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.09 |
2026-03-31 | -$0.10 |
2025-12-31 | -$0.22 |
2025-09-30 | -$0.09 |